Improving of psychological status and inflammatory biomarkers during omalizumab for chronic spontaneous urticaria.
Future Sci OA
; 6(9): FSO618, 2020 Aug 10.
Article
en En
| MEDLINE
| ID: mdl-33235810
ABSTRACT
BACKGROUND:
Depression and anxiety are the most common psychiatric comorbidities in chronic spontaneous urticaria (CSU). Omalizumab is a monoclonal antibody approved for CSU treatment. We evaluated the prevalence of anxiety and depression in CSU patients before and after treatment with omalizumab. MATERIALS &METHODS:
A total of 30 patients were enrolled in the study 15 patients affected by CSU and treated with omalizumab and the other 15 healthy subjects did not receive any systemic therapy. All patients were evaluated using Hospital Anxiety and Depression Scale, CRP and erythrocyte sedimentation rate, at baseline and after 6 months.RESULTS:
The omalizumab group after 6 months of therapy had a decrease of all the scores and biomarkers.CONCLUSION:
Omalizumab allowed an improvement of urticaria and mental comorbidities.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Risk_factors_studies
Idioma:
En
Revista:
Future Sci OA
Año:
2020
Tipo del documento:
Article
País de afiliación:
Italia